Download presentation
Presentation is loading. Please wait.
Published byHadi Kusumo Modified over 5 years ago
1
A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous revascularization Hosam El Sayed, MD, PhD, Richard Kerensky, MD, Michael Stecher, MD, Prasant Mohanty, MBBS, Mark Davies, MD, PhD Journal of Vascular Surgery Volume 63, Issue 1, Pages e1 (January 2016) DOI: /j.jvs Copyright © 2016 Society for Vascular Surgery Terms and Conditions
2
Fig 1 Patient flow diagram.
Journal of Vascular Surgery , e1DOI: ( /j.jvs ) Copyright © 2016 Society for Vascular Surgery Terms and Conditions
3
Fig 2 The Kaplan-Meier curve compares the cumulative freedom from restenosis at long-term follow-up. The trend in the treatment benefit observed at 4 months after the procedure (restenosis rates of 9% in the standard of care [SOC] group and 0% in the Xilonix group) diminished during the course of the study. At 12 months, the restenosis rates were not different between the Xilonix and SOC groups; 27% (6 of 22) Xilonix patients and 24% (5 of 21) SOC patients experienced target vessel restenosis (log-rank, P = .79). Journal of Vascular Surgery , e1DOI: ( /j.jvs ) Copyright © 2016 Society for Vascular Surgery Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.